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Abstract  
Before going deeper and deeper to study the kidney and its roles, let’s explain the main points that affects 
mechanisms through which it works. We start with transforming growth factor β1 (TGF-β1), which is a 
multifunctional growth factor with an important role in development, cell proliferation, matrix deposition, 
modulation of the, immunity, regulation of embryonic development and cellular differentiation and apoptosis 
(programmed cell death). It is considered as a significant mediator of glomerular and tubulointerstitial 
pathobiology in chronic kidney diseases[1]. Over-expression of TGF-β can induce renal fibrosis, causing kidney 
disease, and ultimately end-stage renal disease (ESRD). Recent developments have found that, using certain 
types of protein antagonists such as a  receptor ligand or drug that does not induce a biological response itself 
upon binding to a receptor but  sequential activation of two serine/threonine kinase receptors, the type I and type 
II receptors.  A third receptor, betaglycan serves as a co-receptor for TGF-β1. Recent reports indicate that 
membrane anchored betaglycan may play an inhibitory role in TGF-β1 signalling. This inhibitory role of 
betaglycan is a function of the heparan sulphate composition of the betaglycan glycosaminoglycan [2]. We can 
say that, the expression of betaglycan and its augmentation by cytokines treatment in HK2 cells has been 
described. By concentrating on TGF-β activity, it is shown that knock-down by siRNA and inhibition of 
glycoslation of  betaglycan antagonize signalling by TGF-β end production of EMT.  This work suggests that 
betaglycan could be a major mediator of PTC activation in vivo. blocks  reverse the effects of renal fibrosis [3]. 
Keywords: α-SMA;(Alpha- Smooth Muscle Actin). DNA; (Deoxyribonucleic Acid). ECM; (Extracellular 
Matrix). EMT; (Epithelial-Mesenchymal Transition). GAPDH; (Glyceraldehyde-3-phosphate dehydrogenase). 
HK-2 (Human Kidney-2). mRNA; (Messenger Ribonucleic Acid). PAGE; (Polyacrylamide Gel 
Electrophoresis). PCR; (Polymerase Chain Reaction). P-Smad;(Phosphorylated-Smad). Q- PCR; (Quantitative 
PCR). RNA; (Ribonucleic Acid). RT- PCR; ( Reverse transcriptase-PCR). TGF-β; (Transforming growth factor-
Beta).  
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1. Introduction  
Tubulointerstitial fibrosis is a well-known finding of chronic renal disease, irrespective of the aetiology of the 
diseases and is considered as the major lesion of end-stage renal diseases such as glomerulonephritis as a 
primary inflammation, diabetic nephropathy as a metabolic dysfunction, and cystic nephropathy as structural 
malformations. The normal interstitium is a complicated structure of collagen, fibronectin, non-collagenous 
glycoproteins and proteoglycans.  Interstitial fibrosis is characterized by excessive synthesis and accumulation 
of these and other ECM substances [4]. Thus the intersitium expands causing derangement of tubulointerstitial 
structure and changes of the normal physiological function and subsequently gradual deterioration of renal 
function. Progressive loss of renal function is associated with development of glomerulosclerosis  and with  
interstitial fibrosis as well.  Interstitial fibrosis is characterized by the destruction of renal tubules and interstitial 
capillaries as well as by the accumulation of extracellular matrix proteins [5]. As inerstitial fibrosis, related to 
accumulation of  ECM , it also related to progression of   renal disease with accumulation of fibroblasts and 
myofibroblasts which is related to nephron loss and kidney shut down, so considered as a predictor of fibrotic 
progression [6]. Moreover, previous studies have shown that reduction in the glomerular filtration rate is better 
correlated with tubulointerstitial injury than with glomerulosclerosis) [7]. 
Several factors, including cytokines and growth factors such as Transforming Growth Factor βI (TGF-βI) 
activate tubular cells and lead to this pathogenesis. Activated tubular cells secrete increased amounts of 
chemokines and cytokines into the peritubular interstitium. Activated tubular cells may themselves increase the 
formation of peritubular extracellular matrix as well [8]. 
Immune responses of tubular epithelial cells are induced by exposure to proteins e.g. stimulation of the release 
of various cytokines, including TGF-β1[9]. The release of such cytokines causes differentiation of tubular 
epithelial cells and possibly tubular epithelial cells into myofibroblasts. This change of phenotype is 
characterized by de novo expression of alpha-smooth-muscle actin [10]. A specific gene Fsp1 (fibroblast-
Specific Protein-1) [11], has been cloned, which triggers the transformation of tubular epithelial cells into 
myofibroblasts [12], in response to cytokines, such as TGF-β.  Studies revealed that tubulointerstitial disease 
was a more reliable predictor of functional impairement than was glomerular injury in a variety of renal diseases 
e.g. membranoproliferative  glomeriulonephritis, diabetic glomeriulosclerosis, glomerular amyloidosis etc.[13]. 
Different sources of fibroblasts in organ fibrosis. Four possible mechanisms are depicted. One study suggests 
that about 12% of fibroblasts are from bone marrow, about 30% can arise via local EMT involving tubular 
epithelial cells under inflammatory stress, and about 35% are from EndMT [14]. Activation of resident 
fibroblasts or other mesenchymal cells, such as perivascular smooth muscle cells/pericytes and fibrocytes [15]. 
The remaining percentage likely emerge via proliferation of the resident fibroblasts and other still unidentified 
sources. Systemic treatment of mice with renal fibrosis with recombinant human BMP-7. The bone 
morphogenetic proteins  (BMPs) reverses renal disease due to severe attenuation of the formation of EMT- and 
EndMT-derived fibroblasts. EMT is a process usually associated with an increase in cell motility and fibrotic 
sequelae with the accumulation of a newly expressed extracellular matrix (ECM). Various signalling pathways 
are involved in EMT.  Some proteins are transcriptional repressors of  E-cadherin and their expression induces 
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EMT. Recently, activation of the phosphatidylinositol 3' kinase (PI3K)/AKT axis is emerging as a central 
feature of EMT [16]. A prototypical feature of epithelial cells undergoing an EMT‐process is reduced and 
finally  lost expression of the epithelial marker E‐cadherin, a member of the    adherent junction protein 
family[17]. 
2. Materials  and Methods  
Those have been used in this Abstract : 
1. Conventional PCR. 
2. Semi-Quantitative Polymerase chain reaction. 
3. Quantitative Polymerase chain reaction (Q-PCR). 
4. Western Blot Analysis. 
5. Reporter Gene Analysis. 
6. Statistical Analysis. 
These methods have been shown in each experiment in this abstract. 
2.1.Transforming Growth Factor Beta TGF-β   
 
Figure 1: Shows the structure of Transforming Growth Factor Beta with its N and C  terminals with small and 
large latent complexes. 
Adapted from: www.biochemj.org/bj/352/0601/bj3520601f01.jpg, Rahmi ÖKLÜ, and Robin HESKETH 
2.2. Adapted from : researchblogs.duke.edu/jas83 
There are five receptors regulating SMADs: SMAD1, SMAD2, SMAD3, SMAD5, and SMAD9 (sometimes 
referred to as SMAD8) figure 2 above. There are essentially two intracellular pathways involving these R-
SMADs. TGF beta's, Activins, Nodals and some GDFs (Growth and differentiation factors (GDFs) are mediated 
by SMAD2 and SMAD3, while BMPs (Bone morphogenetic proteins ), AMH(Anti-mullerian hormone) and a 
few GDFs are mediated by SMAD1, SMAD5 and SMAD9.  Binding of transforming growth factor beta (TGF-
β) to its cell surface receptor Type II leads to the phosphorylation of the Type I receptor by Type II. The Type I 
American Scientific Research Journal for Engineering, Technology, and Sciences (ASRJETS) (2018) Volume 50, No  1, pp 22-49 
25 
 
receptor is then able to phosphorylate and activate the SMAD2 protein. Smad2, with Smad4, is translocated to 
the nucleus where the activated Smad complex recruits other biological effects of TGF-b, the above explained 
pathway called the classical signalling pathway of TGF-β (Figure 4). There are also Smad-independent 
pathways activated by TGF binding its receptors as Rho,MAPK,PKC,Cross-talk TGF-β signalling and Wint 
pathways. 
 
Figure 2: Signalling Pathways of TGF-β. The classical signalling pathway  
2.3. Betaglycan (TGF-β RIII)  
Betaglycan is Transforming Growth Factor Beta receptor III (TGFBR3), (figure-3) and identified as an 
accessory receptor for the  TGFβs  is a cell-surface chondroitin sulfate / heparan sulfate proteoglycan, its 
molecular weight is about >300 kDa.(figure 3,10). It is a transmembrane  proteoglycan with a large extracellular 
domain that binds TGF-β with high affinity but lacks a cytoplasmic signaling domain [18]. It is formed from 
heparin and chondroitin sulphate, core protein, ectodomain part, with its N and C terminals binding to ECM and 
cytoskeleton (Figure 3). Betaglycan binds to various members of the TGF-beta of ligands by its superfamily 
core protein, and bFGF (basic fibroblast growth factor), via its heparan sulfate chains. It is not involved directly 
in TGF-beta signal transduction but by binding to different member of the TGF-beta superfamily at the Cell 
surface,  it acts as a reservoir of ligand for TGF-beta receptors[19]. 
Betaglycan is known to be a proteoglycan TGF-β co-receptor for TGF-β ligands, it is undergoes ectodomaine 
cleavage and production of a soluble ectodomain fragment which is stable in presence of  betaglycan and if we 
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treat the cells that express betaglycan with inhibitors of intramembrane protease γ-secretase, it stabilizes this 
fragment means that it is a γ-secretase substrate, all of these are independent of the effects of TGF-β. 
So transmembrane-cytoplasmic fragment will be stable after betaglycan cleavage, this gives rise to an 
implication for TGF-β effects and response. 
Betaglycan is important regulator of development, differentiation and tumor metastasis, it modulates some 
effects of TGF-β, it binds the three TGF-β isoforms through two binding sites on the core ectodomain also 
enhances TGF-β signalling by increasing affinity of the ligand forTGF-βII, on the other hand, it has also an 
inhibitory function by binding to TGF-β members. Betaglycan undergoes ligand-independent ectodomain 
shedding and a stable soluble fragment is produced which sequesters TGF-β. This fragment has got a 
therapeutic significant in some tumors and fibrosis as an inhibitor of TGF-β signaling. In addition to the 
betaglycan ectodomain it has also cytoplasmic domain which modulates TGF-β dependent and independent 
activation of p38/MAPK which still not well known, betaglycan also forms a complex with syndcan-2 which is 
important in regulating TGF-β signalling and fibrosis. 
So investigations to explore the fate of betaglycan fragment after ectodomain cleavage is our target, so 
betaglycan ectodomain cleavage considered a substrate for γ-secretase and betaglycan transmembrane-
cytoBetaglycan is known to be a proteoglycan TGF-β co-receptor for TGF-β ligands, transmembrane-
cytoplasmic fragment will be stable after betaglycan cleavage, this gives rise to an implication for TGF-β effects 
and response. 
Endogline despite of being functionally important, it is found in two forms, its mutation yields impaired 
coordination of TGF-β signalling complexes and play a role in controlling cell migration and adhesion 
composition. 
Ectodomain shedding and γ-secretase-dependent release of an intracellular domain, an implication is important 
TGF-β signal transduction, on the other hand γ-secretase inhibition also has a significant impact on TGF-β 
signalling.   
Betaglcan species have opposing effects on TGF-β signalling whereby betaglycan serving as ( molecular switch) 
.when isolated  betaglycan cytoplasmic domain is inhibited it leads to decrease TGF-β signaling through 
activation of the p38/MAPK pathway, so betaglycan has got an essential role in mediating the specificity of 
TGF-β signaling pathways.   
The structure of betaglycan,(figure 3) is a polymorphic membrane-anchored proteoglycan with high affinity for 
transforming growth factor-β (TGF-β).  As produced from its cDNA sequence, the 853 amino acid core protein 
of  betaglycan has an extracellular domain with different sites for glycosaminoglycan (GAG) chains attachment. 
Despite these chains not being necessarily important for TGF-β binding to the core protein, they are an 
important component of connective tissues, and may be covalently linked to a protein to form proteoglycans. 
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Figure 3: Structure of betaglycan  
Betaglycan appears to deliver TGF-β to the signaling receptors [20]. Betaglycan binds TGF-β through the core 
protein [21]. The localization of the TGF-β-binding site in betaglycan is unclear. There are at least two 
independently active TGF-β binding sites in betaglycan, one in the N-terminal two thirds of the extracellular 
domain of betaglycan and another in the C-terminal one-third. These binding sites exhibit similar binding 
specificities and representing the N-terminal and C-terminal binding sites enhance the bioactivity of TGF-β. 
This enhancing effect was observed not only in the growth 
inhibitory activity of TGF-β but also in the stimulating effect of TGF-β on the matrix 
synthesis. In addition to a membrane-bound form, there is a soluble form of  betaglycan as well, generated by 
the ectodomain shedding of the cell surface receptor. Although the membrane-bound form presents ligand, the 
soluble form is thought to sequester ligand from the serine/threonine TGF-ß signalling receptors.  
This sequestering role may be of benefit in later stage tumours, where excess TGF-β may assist in tumour 
growth by enhancing epithelial to mesenchymal transitions, MMP (Matrix metalloproteinase) expression, and 
basement membrane degradation [22]. 
Furthermore,  betaglycan, a cell surface heparan sulphate proteoglycan, is traditionally thought to function by 
binding transforming growth factor type β (TGF-β) via its core protein and then transferring the growth factor to 
its signalling receptor, the type II receptor. Betaglycan induces TGF-β signalling in a ligand-independent 
manner, through activation of the p38 pathway). 
2.4. Betaglycan and Renal fibrosis  
Transforming growth factor-β (TGF-β) is a key mediator in the pathogenesis of renal diseases. Betaglycan, 
which is a type III TGF-β receptor and regulates TGF-β action by modulating its access to the type I and II 
receptors.  Betaglycan potentiates TGF-β; however, soluble betaglycan, which is produced by the shedding of 
the membrane-bound receptor, is a potent antagonist of TGF-β. This was documented to prevent renal damage 
(Adapted online at www.med.unibs.it/%7Eairc/hspgs.htm). 
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in genetically obese and diabetic db/db mice, Because SBG (Soluble betaglycan) has a high affinity for all TGF-
β isoforms, in particular TGF-β2, it is found naturally in serum and tissues and its shedding may be regulated. It 
is believed that SBG will prove convenient for long-term treatment of kidney diseases and other pathologies in 
which TGF-β plays a pathophysiological  role, as it occurs as a Proteoglycan Heparan sulfate (HS) which is a 
linear polysaccharide found in all animal tissues.  It occurs as a PG in which two or three HS chains are attached 
in close proximity to cell surface or extracellular matrix proteins[23]. 
The major cell membrane HSPGs are the transmembrane syndecans (GPI) anchored glypicans. Other forms of 
membrane HSPG include betaglycan and the glycosylphosphatidylinositol [24] . 
In contrast to membrane betaglycan, SBG inhibits TGF-β binding to kinase receptors and thereby works as a 
TGF-β antagonist [25]. The administration of SBG to db/db mice, resulted  in a reduction in kidney damage, 
Plasma creatinine concentration,  albuminuria, and mesangial matrix expansion, [26], were significantly reduced 
by the treatment with SBG, So it has been  shown that SBG treatment of db/db mice significantly ameliorates 
the progression of kidney dysfunction, without any apparent negative side effect, as indicated by the absence of 
gross macroscopic damage of internal organs[27]. 
Betaglycan (BG) has a dual role in the modulation of TGF-β activities (Figure 4).  BG, potentiates TGF-β 
actions when it is membrane bound. Shedding of BG extracellular region generates the soluble form of the 
receptor.  Soluble BG still binds TGF-β with the high affinity of the membrane BG, but instead of presenting it 
to the type II receptor, soluble BG sequesters it and thus neutralizes its actions[28]. Unique among other TGF-β 
inhibitors is the fact that BG may be subject to regulated shedding of its ectodomain [29], making possible, in 
principle, control of the relative ratio of the membrane and soluble forms of the receptor, providing a way to 
switch TGF-β actions on or off. SBG is a renoprotective agent that neutralized TGF-β actions in this model of 
nephropathy. Because SBG has a high affinity for all TGF- isoforms, in particular TGF-β 2, it is found naturally 
in serum and tissues and its shedding may be regulated. We believe that SBG will prove convenient for long-
term treatment of kidney diseases and other pathologies in which TGF- plays a pathophysiological role [30]. As 
inerstitial fibrosis, related to accumulation of  ECM , it also related to progression of   renal disease with 
accumulation of fibroblasts and myofibroblasts which is related to nephron loss and kidney shut down, so 
considered as a predictor of fibrotic progression [31]. This myofibroblasts express alpha smooth muscle actin 
that is related to intracellular stress fibres, in advanced disease, the interstitium becomes filled with 
myofibroblasts. Myofibroblasts are derived from a variety of sources including resident mesenchymal cells, 
epithelial and endothelial cells which is called epithelial/endothelial-mesenchymal (EMT/EndMT) transition, 
and from circulating fibroblast-like cells called fibrocytes that are derived from bone-marrow stem cells [32] .  
There is also what is called exosomes which could trigger  elevated α-smooth muscle actin expression and 
differentiate fibroblast into myofibroblasts, this exosomes are vesicles secreted by diverse cell types that play 
complex roles in intercellular communication. Betaglycan did not alter TβRI or TβRII but instead inhibit Smad 
2/3, Akt and ERK phosphorylation and we can say that betaglycan is important for TGF-β signalling and 
differentiation in myofibroblast, through smad dependent and independent pathways. While the Smad pathway 
is essential for TGF-β singnaing it also signal a variety of  Smad-independent pathways as mitogen–activated 
protein kinase ( MAPKs ) and phosphatidylinositol 3-kinase (P13k)-Akt. Betaglycan is a transmembrane 
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proteoglycan and shows a large extracellular domain which having heparin and chondroitin sulphate 
glycosaminoglycan chain but without kinase domain. 
Copyright ©2007 American Physiological Society
Juarez, P. et al. Am J Physiol Renal Physiol 292: F321 -F329 2007;
doi:10.1152/ajprenal.00264.2006
Betaglycan (BG) dual modulation of TGF -beta activities
 
Figure 4: Betaglycan has a dual modulation of TGF-β activities 
Betaglycan has an important function in cancer and lost in most of non-small cell lung cancer, its 
downregulation enhances epithelial to mesenchymal transition ( EMT ), betaglycan is downregulated during 
TGF-β differentiation of fibroblasts and this imply the antifibrotic action of betaglycan. Betaglycan undergoes 
ligand-independent ectodomain shedding and a stable soluble fragment is produced which sequesters TGF-β. 
This fragment has got a therapeutic significant in some tumors and fibrosis as an inhibitor of TGF-β signaling. 
In addition to the betaglycan ectodomain it has also cytoplasmic domain which modulates TGF-β dependent and 
independent activation of p38/MAPK which still not well known, betaglycan also forms a complex with 
syndcan-2 which is important in regulating TGF-β signalling and fibrosis. 
 Betaglcan species have opposing effects on TGF-β signalling whereby betaglycan serving as ( molecular 
switch) . when isolated  betaglycan cytoplasmic domain is inhibited it leads to decrease TGF-β signaling 
through activation of the p38/MAPK pathway, so betaglycan has got an essential role in mediating the 
specificity of TGF-β signaling pathways. Genetic analysis to clarify the role of epithelial cells and interstitial 
cells in the generation of myofibroblasts during kidney injury and fibrosis. It has been shown that there is a 
definitive  evidence that kidney epithelial cells do not become myofibroblasts in vivo, but show that interstitial 
pericytes are myofibroblast progenitors in fibrotic kidney disease [33,34]. 
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2.5. The Aim of this work 
The purpose of work is to examine the potential role of betaglycan in HK2 cells as a regulator of TGF-β 
signalling in the kidney in terms of expression, inhibition  and any phenotypical changes such as  Epithelial-
mesenchymal transition associated.  
The specific aims are to: 
1. Examine the expression and inhibition of betaglycan. 
2. Examine the effect of specific siRNA and heparin sulphate inhibitors on betaglycan  expression with 
relation to Smad  phosphorylation of TGF-β. 
3. Examine the role of betaglycan  expression on α-sma and E-cadherin (EMT). 
4.         These roles of betaglycan actions will have a potential  impact on TGF-β, which is the  key factor  in 
renal fibrosis. 
2.6. Induction of betaglycan by proximal tubular cells  
The progression of renal disease is correlated with the degree of renal interstitial fibrosis. It has already been 
demonstrated that proximal tubular epithelial cells (PTC) have the potential to contribute to the pathogenesis of 
renal fibrosis directly by alterations in the production of components of the extracellular matrix and indirectly 
by the production of profibrotic cytokines [35;36], and we can see betaglycan expression by Cytokines and 
TGF-β by different methods,( figures 4,5) : 
 
Figure 5: Betaglycan Expression by Conventional PCR  
2.7. Conventional PCR showing betaglycan expression as bands on agarose gel following No 
stimulation, following IL-1 and following IL-6 stimulation compared with actin bands 
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Figure 6: Conventional PCR Confirmation by Quantitative (Q-PCR), Concentration dependent induction (IL-1, 
IL-6 and TGF-β) of betaglycan expression  
To identify the most effective dose of IL-1, IL-6 or TGF-β that produced the greatest betaglycan expression, 
different concentrations of cytokines were used to stimulate HK2 cells at the optimal time which was chosen as 
12 hours.The results revealed that 0.5 ng/ml was the most effective dose for both IL-1 and IL-6 to produce 
maximum betaglycan expression while 10 ng/ml was the most effective dose for TGF-β (Figures 7,8,9) : 
 
Figure 7: Dose Dependent of IL-1 Dose  
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                                                                   Concentration of IL-6 
Figure 8: The most effective dose of the cytokine (IL6) induced BG express. at 12 hours’: 
 
Figure 9: The most effective dose of the cytokine (TGF-β) induced betaglycan expression at 12 hours’ time 
point  
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Figure 10: Betaglycan  and  its  degradation  products 
                                HiMarkTM        Betaglycan and its  Degredation products. 
2.8. Inhibition of Betaglycan Expression and Glycosylation  
knock-down of betaglycan  was achieved by using specific short interfering RNA (siRNA) to investigate the 
optimal time of betaglycan knock-down, what happened to TGF-β1 signalling and any phenotypical changes to 
the immortalized  HK2 cells. Whether the glycosylation of betaglycan was also important for its function was 
investigated using P-nitrophenyl-β-D-xylopyranoside to inhibit glycosylation. 
2.9. Optimising Transfection Time  
The incubation time required for maximal knockdown of the target gene can vary depending on the specific 
siRNA used, and therefore the optimal transfection time for betaglycan was determined prior to further 
experimentation.Betaglycan was knocked-down by transfection with specific siRNA. 
 In the following experiment, determination of the optimal time of knock-down will help; namely at what time 
TGF-β can be best controlled by betaglycan. 
  The concentration of betaglycan siRNA was 20 mmolar, the scramble concentration was 40 pmol per 
microlitre and the end concentration was 33 nm/well. 
 The degree of TGF-βIII knock-down was measured by Q-PCR.  Cells were transfected with siRNA and mRNA 
extracted for times up to 72 hours.  
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 Knock-down was found to be maximal at 12 hours onwards (Figure 11).  At 24 hours 80% knock-down which 
was highly significant (Figure 11). 
 
Figure 11: Optimising Transfection Time  
2.10. The bar graphs showing the best time for betaglycan knock-down, every group done individually and 
compared to its own scramble 
The effect of betaglycan siRNA on Smad-III phosphorlation was also carried out by SDS-PAGE and Western 
blotting was revealed a significant change of P-smad-III phosphorylation (Figure 12). 
 
Figure 12:  Betaglycan core protein inhibition by betaglycan siRNA transfection  
 Starting with the growing of HK2 cells until they become 50% confluent, they were kept in serum free media 
overnight then transfected with siRNA and incubated for 72 hours.  
0
0.2
0.4
0.6
0.8
1
1.2
1.4
6H 12H 24H 48H 72H
R
el
a
ti
v
e 
ex
p
re
ss
io
n
 o
f 
b
et
a
g
ly
ca
n
Series1
Series2
Scramble
Betaglycan knockdown
*** *
***
American Scientific Research Journal for Engineering, Technology, and Sciences (ASRJETS) (2018) Volume 50, No  1, pp 22-49 
35 
 
The cells were then extracted for protein analysis by SDS-PAGE and Western blotting carried out.   
There was a marked reduction in betaglycan protein expression in knocked-down cells (Figure 13), Samples 
were compared to GAPDH.  U = untransfected samples, S = Scrambled, B(-) = betaglycan knock-down. 
 
Figure 13: Here betaglycan prevents P-smad III of being expressed. HK2 cells were transfected and  30 
Western blotting carried out.  GAPDH has been used for comparison. ST = Scramble + TGF-β,  B(-)T = 
betaglycan knock-down + TGF-β.  The relationship of betaglycan knock-down on TGF-β signalling in terms o 
P-smad-III phosphorylation changes which were used at different time intervals. 
2.11. The relationship between betaglycan and TGF-β1 signalling following treatment with P-nitrophenyl-β-
D-xylopyranoside (Dual Luciferase Enzyme Reporter) 
The dual luciferase reporter assay (Promega) has been used to show how inhibition of betaglycan heparan 
sulphate with  P-nitrophenyl-β-D-xylopyranoside regulates and affects TGF-β signalling (Figure 14).  
Removal of betaglycan heparan sulphate in epithelial cells increases the ratio of TGF-β1 binding to TβR-II and 
TβR-I, attenuates degradation of TGF-β1.  
 augments TGF-β1 -induced cellular responses but this action depends on the magnitude of TGF-β as it has been 
known that around one-quarter of TGF-β has been shown to bind to heparan sulphate [43]. 
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Figure 14: The relation between BG and TGF-β following P-N-Xpyranoside  
Preparing the white 96 well plate, 12 wells + 2 blank + 1 extra = 15 wells, dose of P-nitrophenyl-β-D-
xylopyranoside is 0.406 milligram per 500 microlitre in each well, and for Tgf-β is 1 microlitre per ml which is 
equal to 1 ng per ml. Cells transfected with the CAGA-luciferase reporter construct, treated with P-nitrophenyl-
β-D-xylopyranoside (single dose), Tgf-β stimulation was at 6 hours.  Four groups used in the experiment 
(Control, Tgf-β, PXY, Both).  The samples were incubated for 72 hours with the inhibitor. This experiment was 
repeated three times. ┬ = Standard deviation. * = P-value = ˂ 0.05 = Statistically significant = ˂ 0.05  , ** = P-
value = highly significant = ˂ 0.03 , Control = Neither XY nor TGF-β was applied. XY = P-nitrophenyl-β-D-
xylopyranoside. 
As has been seen from the previous experiment (figure 14), the inhibition of the active part of  betaglycan 
(Heparan sulphate) has brought down TGF-β luminescence level. These results suggest that heparan sulfate 
modulates TGF-β1 responsiveness by decreasing the ratio of TGF-β1, thus diminishing signalling of TGF-β1 in 
the epithelial cells[44]. 
Generally betaglycan has an important impact on TGF-β signalling as it affects the core protein expression and 
subsequently the cell functions, when betaglycan blocked, its bands down-regulated and phosphorylation of  P-
smad III has changed, which shows how significant betaglycan (TGF-β-R III) could manage TGF-β signalling 
in the kidney. 
2.12. The effect of P-nitrophenyl-β-D-xylopyranoside treatment on betaglycan protein 
Betaglycan and TGF-β1 signalling association were examined by Dual Luciferase Enzyme Reporter assay with 
P-nitrophenyl-β-D-xylopyranoside treatment.   Betaglycan protein was down regulated as seen by the Western 
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blotting experiment which was regulated by treatment with P-nitrophenyl-β-D-xylopyranoside (Figure 15). 
 
Figure 15: The effect of P-nitrophenyl-β-D-xylopyranoside treatment on betaglycan core-protein expression  
Incubation period of P-nitrophenyl-β-D-xylopyranoside was 72 hours. The effect of P-nitrophenyl-β-D-
xylopyranoside treatment (The betaglycan functional part inhibitor, heparan sulphate), as it affects betaglycan 
protein expression, results assayed with GAPDH.  High molecular weight ladder was used to visualize the high 
molecular weight betaglycan size.  This experiment was repeated 3 times and gave the same result. T = TGF-β, 
XT = P-nitrophenyl-β-D-xylopyranoside + TGF-β.   
2.13.  Effect of P-nitrophenyl-β-D-xylopyranoside treatment on P-Smad-III 
The purpose of this experiment was to show how P-nitrophenyl-β-D-xylopyranoside was affected TGF-β core-
protein (the P-Smad-III) which was visualised by Western blotting.  After transfection of HK2 cells with P-
nitrophenyl-β-D-xylopyranoside treatment, stimulation with TGF-β was done at 15, 30, 60 and 120 minutes then 
scraping of the protein and proceeding to SDS-PAGE and Western blotting as described in the methods (section 
2.11), which revealed a significant change of P-smad-III phosphorylation, results assayed by GAPDH,  and here 
supports that P-nitrophenyl-β-D-xylopyranoside through inhibition of heparan sulphate, betaglycan core protein 
and subsequently TGF-β found to be down regulated [45], as shown in (Figure 16). 
 
Figure 16:  Effect of P-nitrophenyl-β-D-xylopyranoside treatment on P-smad-III 
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2.14. The Function of Betaglycan  
The potential impact of betaglycan as a marker of epithelium (E-cadherin) or mesenchymal cells (α-sma) is 
studied in this chapter. Cadherins are calcium-dependent adhesion molecules and members of a class of type-1 
transmembrane proteins. They have important roles in cell adhesion and contribute to mechanisms controlling 
how cells within tissues are bound together.  
The cadherin superfamily includes cadherins, protocadherins, desmogleins, and desmocollins. In structure, they 
share cadherin repeats, which are the extracellular Ca2+-binding domains [46], Loss of both E-cadherin 
expression and function, has been implicated in cancer progression and metastasis. E-cadherin down-regulation 
decreases the strength of cellular adhesion within a tissue, resulting in an increase in cellular motility.  This in 
turn may allow cancer cells to cross the basement membrane and invade surrounding tissues.Actin is the 
monomeric subunit of two types of filaments in cells: microfilaments, one of the three major components of the 
cytoskeleton, and thin filaments, part of the contractile apparatus in muscle cells. Thus, actin participates in 
many important cellular processes including muscle contraction, cell motility, cell division and cytokinesis, 
vesicle and organelle movement, cell signalling, and the establishment and maintenance of cell junctions and 
cell line.  Alpha smooth muscle actin is a protein that in humans is encoded by the ACTA2 gene located on 
10q22-q24 [47]. The alpha smooth actin is found in muscle tissues and is a major constituent of the contractile 
apparatus[48]. It can be used for evaluation of the disease activity and prognosis as its expression increased  by 
mesangial cells from GN patients in the kidneys [49]. The expression of α-smooth muscle action (α-SMA) in the 
renal tubulointerstitium in patients with kidney collateral stasis was increased with the increasing of the degree 
of renal interstitial fibrosis, as there was a significant positive correlation between kidney collateral stasis and α-
SMA expression [50] . So expression of alpha-smooth-muscle actin (ASMA) has suggested a new way to assess 
clinical implications in the kidney.The effect of betaglycan on  TGF-β- dependent phenotypical changes in 
human immortalized HK2 has been examined (Figure 17). The effect of knock down of betaglycan on E-
cadherin and  alpha-smooth-muscle actin has been used to investigate whether the effect of betaglycan on TGF-
β induced signalling resulted in changes in markers of EMT. 
 
Figure 17: Demonstration of the HK2 cell functions in terms of betaglycan expression after being knocked-
down then stimulated by TGF-β: 
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This Q-PCR bar graph illustrates betaglycan Expression after betaglycan knock-down then TGF-β stimulation at 
different time points, every sample compared to the  scramble. 
2.15. Demonstration of E-cadherin expression by HK2 cells after betaglycan knock-down and TGF-β 
stimulation 
E-cadherin expression as an element of EMT in HK2 cells was investigated after betaglycan knock-down in the 
presence of TGF-β stimulation to examine whether there was an association of betaglycan with EMT. The result 
was that, E-cadherin was down regulated when betaglycan down regulated or lost (figure 18) which suggested 
that there was an element of EMT in most of the time points. 
 
Figure 18: Q-PCR illustrates E-cadherin expression after BG knock-down and TGF-β stimulation  
Q-PCR illustrates the E-cadherin expression after betaglycan knock-down and TGF-β stimulation at different 
time points, every sample compared to the scramble one 
2.16. Demonstration of α-sma expression of HK2 cells after betaglycan knock-down and TGF-β stimulation 
Alpha smooth muscle actin  expression as an element of EMT in HK2 cells was investigated after betaglycan 
knock-down in the presence of TGF-β stimulation to examine whether there was an association of betaglycan 
with EMT. This is done by Real-time quantitative PCR(figure 19). The result of α-sma was mildly up-regulated 
which suggested that there was an element of EMT when betaglycan was lost. 
 
Figure 19: Q-PCR illustrates α-sma expression after betaglycan knock-down and TGF-β stimulation 
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2.16.  Relationship of betaglycan to PAI-1( Plasminogen activator inhibitor-1)   
The purpose of the experiment was to determine whether betaglycan knock-down induced TGF-β down 
regulation as a direct action or through PAI-1 which is the mean TGF-β inducer.  In this experiment, when TGF-
β applied, PAI-1 expression increased that means betaglycan knock-down does not depends on PAI-1 
action.Type-1 inhibitor of plasminogen activator (PAI-1) is an important physiological regulator of extracellular 
matrix (ECM) homeostasis and cell motility. TGF-β1, in particular, is a powerful inducer of matrix 
deposition/turnover, cell locomotion and PAI-1 expression. Plasminogen activator inhibitor-1 is the main 
inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA), the activators of plasminogen and hence 
fibrinolysis.  High levels of PAI-1 are found in severe sepsis while low levels or deficiency are found in 
bleeding.  Thus plays a role in inflammatory lung disease and malignancy.  It has an important role in renal 
disease where high levels of PAI-1 are found in nephritic and haemolytic uremic syndrome. 
The following experiment, tries to determine the relationship between PAI-1 and betaglycan,  and as TGF-β 
induces PAI-1, (figure 20).  Starting the experiment which lasts 48 hours in triplicate samples, mRNA was 
isolated, reverse transcribed, then quantified by Real-time quantitative PCR. The result of PAI-1 was down 
regulated but when TGF-β was given, PAI-1 expression was increased, that means PAI-1 has no relationship 
with betaglycan when it acts on TGF-β which instead it has been induced leading to relatively increased PAI-1 
expression (Figure 20). 
 
Figure 20:  Plasminogen activator inhibitor-1 and BG. Relationship  
The above is  Q-PCR Paragraph of PAI-1 Expressions following betaglycan knock-down with and without Tgf-
β stimulation at different time points, every sample compared to the  scrample one. 
Fibrosis might occur in a variety of organs which are mainly composed of epithelial cells, such as kidney, lung 
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and the liver[51] . Inflammatory signals derived from proliferating interstitial fibroblasts and inflammatory cells 
lead to an expanded ECM and fibrosis. The analyses of diseased human kidney biopsies, revealed the 
appearance of EMT markers [52] . There is also the generation of myofibroblasts by the proximal tubular 
epithelial cells via EMT[49] . In addition, there is evidence in‐vitro that EMT phenotypes occur in different non‐
malignant epithelial cells of different origin. This includes renal, hepatic and pulmonary cells in which a process 
associated with the expression of mesenchymal marker proteins which can be induced by different stimuli as 
TGF-β and Proteinase-activated receptors (PARs). [53]. 
TGF-β, α-sma and E-cadherin have a relationship with betaglycan regarding its expressions and  knock-down.  
All of these subsequently have an impact on HK2 cells.  TGF-β produced a high level of betaglycan expression, 
and this was shown in the previous chapters but when betaglycan knocked-down, its expression dropped down, 
that means TGF-β biological activity can be controlled. Transforming growth factor-β (TGF-β) is a key 
mediator in the pathogenesis of renal diseases but TGF-β activity has been reduced during betaglycan knock-
down, so kidney diseases and fibrosis can be reduced. This renoprotective advantage of betaglycan is induced 
by its soluble form which binds TGF-β with the high affinity of the membrane betaglycan, but actions [instead 
of presenting it to the type II receptor, soluble betaglycan sequesters it and thus neutralizes its 54]. 
E-cadherin and α-sma expression can also be explored when betaglycan knocked-down. That was evident when 
samples compared to the 1st scramble did occur during EMT, with E-cadherin expression reduced while  α-sma 
expression was increased and that supports EMT as an effect of betaglycan knock-down, this effect was found 
to be mild, and this is where the role of betaglycan comes, its presence will reduce EMT effect. 
 Once the relationship of  betaglycan and TGF-β  signalling was determined and TGF-β is an inducer of PAI-1,  
betaglycan̕s relationship with PAI-1 could also be studied, and there was no direct action, but when TGF-β was 
applied, PAI-1 expression increased and that supports the argument that betaglycan has no relation with PAI-1 
but a direct action with TGF-β which is the mean inducer of PAI and there might be other mechanisms have 
been involved as cells were  more reactive to TGF-β. It has clearly been shown in this chapter that betaglycan 
has an important role in reducing epithelial-mesenchymal transformation (EMT). 
3. General Discussion  
The aim of this thesis was to explore the role of betaglycan as a potential regulator of TGF-β signalling in the 
kidney. It has been found that betaglycan has been expressed by human PTC in culture either without 
stimulation or when PTC stimulated at the level of the mRNA or at protein level and this could be inducible by 
the cytokines namely IL-1, IL-6 and TGF-β, this emphasises the potential importance of betaglycan in PTC 
(Proximal tubular cells) as a contributor  to the pathogenesis of renal fibrosis either by alteration of extracellular 
matrix or by production of  profibrotic cytokines such as IL-1, IL-6 and TGF-β.  These cytokines have 
significant cell interaction with betaglycan and its activation, and therefore provide different degrees of 
expression. 
Since HK2 cells express betaglycan, so do the cytokines (IL-1, IL-6 and TGF-β), this result supports the 
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argument that betaglycan expression is essential for optimal TGF-beta signalling. These have been proved by 
Conventional PCR and confirmed by Q-PCR where betaglycan has shown a maximum expression during 24 
hours.  Other cells such as colon goblet cells express normal levels of betaglycan protein [55], Cardiac 
endothelial cells that undergo epithelial-mesenchymal transformation express betaglycan [56]. Now this has also 
been seen with HK2 cells of the kidney. On the other hand, instead of expression, betaglycan can be knocked-
down by betaglycan siRNA transfection or interference with its heparin sulphate composition, which considered 
to be as a beneficial effect of betaglycan, an example of that was in treating fibrosis as its knock-down reduce 
TGF-β expression in mediating fibrosis. Another example where it inhibits the fibrous airway obliteration in a 
rat model of Bronchiolitis obliteran [57]. Furthermore, betaglycan knock-down is resulted in decreased growth 
and motility of human breast cancer, both in vitro and in vivo [58]. This knock-down has been determined at 
what time that can be best achieved. 
 It has been shown that betaglycan was necessary for mediating TGF-β1 signalling through Smad 3 
phosphorylation and that heparan sulphate was also crucial for TGF-β1.  It was also demonstrated that the TGF-
β1 induced change in phenotype depended on betaglycan expression and heparan sulphate synthesis. 
On the opposite angle of the scale, loss of betaglycan contributes to the pathogenesis of GCTs (Granulosa cell 
tumour), [56], and other cancers. Defining the physiological function and mechanism of betaglycan action and 
alterations in betaglycan activity during cancer progression should allow more effective targeting of betaglycan 
and betaglycan mediated functions for the diagnosis and treatment of human cancer [59]. Betaglycan might play 
a prominent role in development and progression of  NSCLC (non-small cell lung cancer) and correlate with 
NSCLC invasion and migration as its expression observed to be reduced [60]. 
Human  betaglycan mRNA is negatively regulated by TGF-β1 in ovarian and breast cancer cells. This regulation 
is dependent on TβRI/ALK5(ALK5 = TGF-β receptor gene) and occurs at the transcriptional level on the 
betaglycan gene [58]. Loss of betaglycan expression can cause  ovarian and other cancers, this seems to be due, 
at least in part, to genetic silencing [59]. Furthermore, betaglycan expression is frequently decreased or lost in 
human cancers (i.e. 65% of breast cancers and 60% of prostate cancers). 
An oncogenic role for betaglycan in human breast cancer cells and mouse mammary tumour cells has been 
shown by Knock-down of betaglycan in these cells and it resulted in decreased growth and motility, both in 
vitro and in vivo [61]. Betaglycan suppresses cancer progression, in part, by reducing cancer cell motility, this 
betaglycan function is independent of its betaglycan signalling role, but with betaglycan activating Cdc42 via its 
interaction with the scaffolding protein beta-arrestin 2 to re-organize the actin cytoskeleton, reduce directional 
persistence and prevent random migration in both epithelial-derived cancer cells and normal epithelial cells [62]. 
Decreased betaglycan expression could be one of the most common mechanisms for TGFβ resistance in human 
cancers. Importantly, increasing or restoring expression of betaglycan in these cancer models decreases cancer 
cell motility and invasion in vitro and angiogenesis, invasion, and metastasis in vivo [63]. 
On the other hand, betaglycan, is a widely expressed heparan and chondroitin sulfate proteoglycan that binds 
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TGF-β with high affinity through its protein core. Changing glycoslation of betaglycan can be achieved by p-
nitrophenyl-β-D-xylopyrinoside treatment.  It does not affect the protein levels of TβR-I binding TβR-II in 
Mv1Lu cells by Western blot analysis.  Heparan sulphate however negatively modulates TGF-β by decreasing 
the ratio of TGF-β1 binding to TβR-II and TβR-I [64 ]. In HK2 cells, the Luciferase reporter assay, revealed that 
P-nitrophenyl-β-D-xylopyranoside brought up TGF-β induced  luminescence and led to TGF-β up-regulation. 
This implies that inhibition of betaglycan heparan sulphate by P-nitrophenyl-β-D-xylopyranoside affects TGF-β 
signalling. 
All of these affect the TGF-β signalling function of HK2 cells of the kidney in terms of physical and 
biochemical function as TGF-β protein expression of its signalling has already been changed, and this shows the 
link between betaglycan and TGF-β.  
Although normally membrane anchored, betaglycan can undergo proteolytic processing in vivo resulting in the 
secretion of a soluble ectodomain.  This ectodomain can both enhance and inhibit signalling depending on the 
concentration of TGF-β1 present, although in most circumstances it is believed to bind and sequester TGF-β, 
functioning as a receptor antagonist. In the kidney, these effects have reduced renal damage progression. This 
emphasises that the relationship between betaglycan and TGF-β1 signalling is complicated because the former 
has shown different regulatory mechanisms upon TGF-β action.  
It was believed that SBG (Soluble betaglyccan) shall prove convenient for long-term treatment of kidney 
diseases and other pathologies in which TGF-β plays a pathophysiological role [65]. Soluble betaglycan, which 
is produced by the shedding of the membrane-bound receptor, is a potent antagonist of TGF-β. inhibitory, but as 
tumorigenesis progresses, TGF-β becomes prometastatic [66]. 
In this thesis, experiments and results of  betaglycan mRNA and core protein were knocked-down and this 
alteration has a role in HK2 cells transition or transformation in terms of minimal loss of  expression of the 
epithelial marker E‐cadherin expression changes, and also mildly increased cytoskeletal proteins α‐SMA (signs 
of EMT). 
Epithelial cells are typically characterized by intercellular adhesion complexes in their lateral membranes which 
enable them to be closely attached to each other and to form cell layers. They display an apico-basal polarity, 
and are separated by the basement membrane from  
other tissues in the body. In contrast to epithelial cells,  mesenchymal cells are capable of moving individually 
through the extracellular matrix since they lack intercellular junctions,and do not display an Apico‐Basal-
polarity [67]. 
Cells that have undergone EMT reveal changes in their migratory capacity and responses to   external signals 
[68]. Not only signalling function, but changes of function as well (EMT) as there was a down regulation of 
betaglycan, mild E-cadherin and α-sma changes, that might be attributed to the Inhibition of Smad2 expression  
with a failure of TGF-β1 to increase α-SMA , confirming the involvement of this signalling in phenotypic 
activation [68]. In contrast, successful  knockdown of Smad3 using siRNA failed to have an impact on TGF-β1-
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mediated phenotypic differentiation [69]. In immortalised HK2 cells, PAI-1 expression decreased when 
betaglycan knocked-down and when TGF-β was applied, and PAI-1 expression increased; that might be 
attributed to the fact that PAI-1 has no relationship with betaglycan or PAI-1 has another pathway of action 
despite being turned up by TGF-β.  
4. Limitations  
There are  some limitations in this work which must be taken into account: Firstly, p-nitrophenyl-β-D-
xylopyrinoside analysis has been used to suppress betaglycan heparan sulphate, and this action is not specific for 
betaglycan as it might inhibit all heparan of other structures (off target). This will have an impact on the result of 
the experiment as heparan sulphate inhibition might be incompleteSecondly, soluble betaglycan has not been 
studied in this work, and if we did, there would have been many results arising from the association of both 
soluble as well as membranous portion of betaglycan, both of which could have resulted in further action on 
TGF-β, the SBG sequester TGF-β while the membranous part heparan sulphate acts as a reservoir of ligand for 
TGF-beta receptors.Thirdly, this work used immortalized HK2 cells as a predictor of renal fibrosis, but the other 
predictor of outcome in the kidney, regardless of disease aetiology, is the presence of myofibroblasts which was 
not studied.  Finally, this work also needs to be applied to and practiced in animal research to get the best 
results, as the HK2 cells have been grown in their normal environment and could express any change that might 
happen in vivo. 
5. The overall conclusion 
Betaglycan can be expressed by HK2 cells spontaneously or by inflammatory cytokines and can also be 
inhibited by siRNA, P-nitrophenyl-β-D-xylopyranoside, and ameliorate fibrosis as well as cancer through a 
group of multiple regulatory mechanisms towards TGF-β1 signalling and also could contributes to EMT. 
Betaglycan acts as apotential regulator of TGF- β1 signalling in the kidney.  
6. Recommendations  
 These groups of betaglycan actions will have a potential impact on TGF-β, which is the key factor in renal 
fibrosis and when combined together they will provide a new weapon in the treatment of kidney fibrosis. 
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